Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Cureus|March 21, 2022
Comparison of SARS-CoV-2 Antibodies and Six Immunoassays in Pediatric and Adult Patients 12 Weeks After COVID-19Imran Saglik, Alparslan Turkkan, Cansu Turan, et al.
Vaccine|July 3, 2015
Children with breakthrough varicella infection requiring hospitalization in Turkey (VARICOMP Study 2008-2013)Ener Cagri Dinleyici, Zafer Kurugol, Ates Kara, et al.
European Journal of Pediatrics|December 15, 2012
The effect of a multispecies synbiotic mixture on the duration of diarrhea and length of hospital stay in children with acute diarrhea in Turkey: single blinded randomized studyEner Cagri Dinleyici, Nazan Dalgic, Sirin Guven, et al.
European Journal of Pediatrics|June 9, 2025
Effect of Limosilactobacillus reuteri DSM17938 to prevent antibiotic-associated diarrhea in children: prospective, multi-center, randomized, placebo-controlled clinical trial (PEARL Study)Ener Cagri Dinleyici, Metehan Ozen, Sirin Guven, et al.
Jornal De Pediatria|May 20, 2015
Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient settingEner Cagri Dinleyici, Nazan Dalgic, Sirin Guven, et al.
Current Medical Research and Opinion|September 19, 2017
Poor outcomes among elderly patients hospitalized for influenza-like illnessMine Durusu Tanriover, Tülay Bagci Bosi, Lale Ozisik, et al.
Vaccines|February 24, 2024
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-UpZafer Sezer, Shaikh Terkis Islam Pavel, Ahmet Inal, et al.
Frontiers in Microbiology|June 28, 2018
Time Series Analysis of the Microbiota of Children Suffering From Acute Infectious Diarrhea and Their Recovery After TreatmentEner C Dinleyici, Daniel Martínez-Martínez, Ates Kara, et al.
Vaccine|December 2, 2022
Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trialsAykut Ozdarendeli, Zafer Sezer, Shaikh Terkis Islam Pavel, et al.
Frontiers in Medicine|May 13, 2025
Vaccination with inactivated SARS-CoV-2 vaccine TURKOVAC induces durable humoral and cellular immune responses up to 8 monthsSeçil Yılmaz, Ahmet Eken, Zafer Sezer, et al.
Pageof 8